Issue 11, 2019

Different solid forms for optimizing route of administration of the herpes drug Pritelivir

Abstract

Pritelivir (AIC316, BAY 57-1293) was discovered as a highly potent drug against herpes simplex viruses with a novel mode of action, i.e. inhibition of the viral helicase–primase. A side by side comparison of the oral form against Valtrex™ in patients with genital herpes, showed superiority in phase II testing for Pritelivir. A number of different solid forms have been generated for additional, e.g. systemic, or topical applications.

Graphical abstract: Different solid forms for optimizing route of administration of the herpes drug Pritelivir

Article information

Article type
Review Article
Submitted
18 Apr 2019
Accepted
05 Aug 2019
First published
09 Aug 2019

Med. Chem. Commun., 2019,10, 1867-1870

Different solid forms for optimizing route of administration of the herpes drug Pritelivir

H. Ruebsamen-Schaeff and H. Buschmann, Med. Chem. Commun., 2019, 10, 1867 DOI: 10.1039/C9MD00233B

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements